Olmetec Plus

Quick links to important sections

Olmetec Plus

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olmetec Plus

Property Description
Active ingredient Olmesartan Medoxomil, Hydrochlorothiazide
Form Oral Film-Coated Tablet (Fixed-Dose Combination)
Pharmacological class Angiotensin II Antagonist and Diuretic
General purpose Management of Essential Hypertension
Rx Status Prescription Only Medicine (POM)

Classification and Composition

Olmetec Plus is a synthetic, prescription-only antihypertensive agent primarily used for the management of essential hypertension in adults. It is classified as an Angiotensin II Antagonist and Diuretic combination, a dual-acting therapeutic approach for blood pressure regulation.

The medication is specifically formulated as a fixed-dose combination (FDC) product, which merges two distinct active ingredients: Olmesartan Medoxomil and Hydrochlorothiazide, into a single oral film-coated tablet. The Olmesartan Medoxomil component belongs to the Angiotensin II Receptor Blocker (ARB) class, while Hydrochlorothiazide functions as a foundational thiazide diuretic.


Therapeutic Principle and Dual Action

The general therapeutic purpose of this medication is to achieve and maintain the consistent reduction of arterial blood pressure to mitigate the associated cardiovascular risk. This dual composition directly contributes to effective pressure reduction, utilizing a therapeutic strategy for managing essential hypertension.

The dual-pathway principle involves the ARB component working to relax blood vessels, which lowers resistance to blood flow, while the diuretic component helps to lower the total circulating fluid volume. These two complementary actions combine to reduce the strain on the heart and arteries, supporting overall blood pressure management.

Regulatory References

  1. NIH DailyMed: Olmesartan Medoxomil and Hydrochlorothiazide Tablets

What side effects are possible with Olmetec Plus ?

Possible Side Effects and Safety Information

The official safety profile for Olmetec Plus (Olmesartan Medoxomil and Hydrochlorothiazide) is established through clinical trial data and post-marketing surveillance, as documented by regulatory agencies. Adverse reactions are classified by frequency and affected body systems.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Effects
Common (1% to 10%) Dizziness, Headache, Nasopharyngitis, Upper Respiratory Tract Infection, Fatigue, Hyperuricemia (increased blood uric acid).
Uncommon (0.1% to 1%) Vertigo, Tachycardia, Angina Pectoris.
Not Known (Post-Marketing) Sprue-Like Enteropathy, Rhabdomyolysis.

Commonly affected System-Organ Classes (SOC) include Nervous System Disorders (e.g., Dizziness), Metabolism and Nutrition Disorders (e.g., Hypokalemia, Hyperglycemia), and Gastrointestinal Disorders.

Serious and Population-Specific Safety Statements

Specific serious adverse reactions are highlighted in regulatory texts. These include Fetal Toxicity, as the medicine is contraindicated in the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus. The label also notes the risk of Acute Myopia and Secondary Angle-Closure Glaucoma associated with the hydrochlorothiazide component, and the risk of Sprue-Like Enteropathy (severe, chronic diarrhea) reported in post-marketing settings.

Safety constraints restrict use in certain groups. The medicine is contraindicated in patients with Anuria (absence of urine production) or severe renal impairment, as well as in those with severe hepatic impairment.

Exposure-Related Safety Patterns

Certain effects are linked to the timing of exposure. Symptomatic Hypotension may be anticipated upon treatment initiation in volume- or salt-depleted patients. Conversely, the increased risk of Non-Melanoma Skin Cancer is observed with increasing cumulative lifetime dose of the hydrochlorothiazide component.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Olmetec Plus (Olmesartan Medoxomil and Hydrochlorothiazide) based on the two core actions of the fixed-dose combination.


Documented Overdose Manifestations

The most likely manifestation of overdosage is hypotension (abnormally low blood pressure), resulting from the combined effects of reduced vascular resistance and fluid loss. Clinical signs that may accompany this include dizziness, faintness, and lightheadedness. Other documented manifestations include tachycardia or, less commonly, bradycardia. Overdose of the hydrochlorothiazide component can lead to significant electrolyte disturbances, such as severe hypokalemia or hyponatremia, and excessive volume depletion.


Required Emergency Actions

Due to the risk of severe outcomes, including profound hypotension and subsequent acute renal failure, regulatory guidance mandates that individuals seek immediate medical attention for a suspected overdose. Instructions include contacting emergency services or proceeding directly to a hospital emergency room. If a patient experiences symptomatic hypotension, the initial procedural step described is to place the patient in the supine position.


Supportive Management

No specific antidote is known for the olmesartan component of this medicine. Management is restricted to symptomatic and supportive treatment. This often involves intravenous infusion of normal saline to correct symptomatic hypotension and fluid deficits, alongside close monitoring of blood pressure, renal function, and electrolyte levels.

Therapeutic Uses of Olmetec Plus

What Olmetec Plus Treats: Main Uses and Benefits

The medicine is commonly used to help manage symptoms related to systemic imbalance in conditions characterized by periods of heightened symptoms, which may include high blood pressure. This medicine is applicable within clinical settings that involve acute or disruptive symptom patterns, and it is generally used for the management of conditions involving systemic or localized discomfort.

Olmetec Plus is commonly used to help address symptoms that create noticeable physiological strain and is applied across domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity. It provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods. The medicine is often used when groups of symptoms appear suddenly or fluctuate, and is considered relevant when short-term symptom stabilization is appropriate. The application of this medicine across domains where additional symptomatic support is needed is relevant in settings marked by temporary physiological stress.

Quick Fact: Relief for Symptomatic Physiological Strain

Eligibility and Restrictions for Use

Eligibility Profile

Official regulatory information outlines specific populations and health conditions that determine eligibility for Olmetec Plus (olmesartan medoxomil and hydrochlorothiazide).

Contraindicated Populations (Must Not Use)

Category Non-Eligibility Condition
Pregnancy/Lactation Second and third trimesters of pregnancy; breastfeeding (lactation).
Organ Function Severe renal impairment (creatinine clearance < 30 mL/min); anuria; severe hepatic impairment, cholestasis, or biliary obstructive disorders.
Allergy Hypersensitivity to the active ingredients or to any sulfonamide-derived drugs.
Metabolic Refractory hypokalaemia, hypercalcaemia, hyponatraemia, or symptomatic hyperuricaemia.
Drug-Specific Concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Restricted or Conditional Use

Patients with mild to moderate renal or hepatic impairment are permitted use only with caution and close monitoring. Use in the pediatric population (under 18 years of age) is not established, and the drug is generally not recommended for patients with Primary Aldosteronism or uncorrected volume/salt depletion.

What should I know about interactions with other medicines?

Olmetec Plus is a combination product whose interaction profile is derived from its two components: olmesartan medoxomil and hydrochlorothiazide (HCTZ).

Documented Interaction Categories

Interaction Type Interacting Agent or Class Interaction-Related Constraint or Risk
Dual RAAS Blockade Aliskiren-containing products, ACE inhibitors, other ARBs Increased risk of hypotension, hyperkalaemia, and decreased renal function. Contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2) when used with aliskiren.
Potassium Alterations Potassium-sparing diuretics, potassium supplements, heparin Increased risk of hyperkalaemia (olmesartan component). Requires serum potassium monitoring.
Renal Function/Fluid NSAIDs (including COX-2 inhibitors) Increased risk of renal impairment and potential loss of the antihypertensive effect.
Exposure/Absorption Colesevelam hydrochloride Decreases olmesartan exposure; a timing-based rule specifies the product should be taken at least 4 hours before colesevelam.
Systemic Toxicity Lithium Increased serum lithium concentrations and risk of lithium toxicity. Co-administration is generally not recommended.
Other Effects Alcohol, barbiturates, narcotics, antidiabetics, cholestyramine/colestipol May potentiate orthostatic hypotension (alcohol/narcotics). Dosage adjustment of antidiabetics may be required (HCTZ component). Thiazide absorption is impaired by cholestyramine/colestipol.

Mechanism of Action

The mechanism of action for Olmetec Plus involves the synergistic effect of two distinct pharmacologic classes: an Angiotensin II Receptor Blocker (ARB) and a Thiazide Diuretic.

Olmesartan Medoxomil Olmesartan is an insurmountable antagonist at the Angiotensin II type 1 (AT1) receptor. Receptor blockade inhibits the physiological actions of Angiotensin II, specifically preventing vasoconstriction, the release of aldosterone, and the proliferation of vascular smooth muscle cells. This action interrupts the Angiotensin II-mediated increase in peripheral vascular resistance.

Hydrochlorothiazide (HCTZ) HCTZ acts in the renal distal convoluted tubule by competitively inhibiting the Na^+Cl^- cotransporter. This molecular interaction reduces the active reabsorption of sodium and chloride ions. The consequent increase in the urinary excretion of sodium, chloride, and water modulates fluid balance and leads to a reduction in plasma volume.

The combined action of AT1 receptor inhibition and plasma volume reduction results in a decrease in total peripheral resistance and a modulation of fluid dynamics.

Dosage and Administration Information

Olmetec Plus is administered orally as a film-coated tablet and is taken once daily (qDay). The medication is officially designated as a step-up therapy and is not indicated for the initial treatment of hypertension. It is intended for use in adults whose blood pressure is not adequately controlled by either of the two components—Olmesartan Medoxomil or Hydrochlorothiazide—when used alone.

The tablet may be taken with or without food and should be consumed at the same time each day to maintain consistent levels. The tablet must be swallowed whole with sufficient fluid and is not to be chewed or crushed. Dosage strengths are fixed combinations, including 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg (Olmesartan/HCTZ). The maximum recommended strength is 40 mg/25 mg. Dose adjustment, or titration, is typically evaluated after two to four weeks of treatment at the current strength.

For specific patient populations, the use of Olmetec Plus includes explicit limitations. The maximum daily dose of the Olmesartan component is restricted to 20 mg in patients with moderate renal or hepatic impairment. Furthermore, the safety and efficacy of this fixed combination product have not been established for the pediatric population (children and adolescents under 18 years of age). If a dose is missed, patients should take the next scheduled dose as usual and not take a double dose to make up for the one they forgot.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Olmetec Plus

This overview describes the types of clinical research conducted for the fixed-dose combination of Olmesartan Medoxomil and Hydrochlorothiazide, summarizing what official studies have examined and what remains to be fully characterized, according to regulatory and scientific records.

Evidence for Use in Essential Hypertension

Research has involved randomized controlled trials (RCTs), a common study design where participants are randomly assigned to receive the medicine, a placebo, or a comparison treatment. These studies often used a factorial design, which is a method for researching the patterns observed with different combinations and doses of the two active ingredients. This research examined patterns in adults with high blood pressure, including those whose blood pressure was not adequately managed by the single-ingredient Olmesartan. Studies were conducted during periods where patients had measurements reflecting physiological strain.

Research highlights changes in measurements during the study period, with studies reporting how blood pressure readings were recorded in the observed groups compared to those receiving other doses or placebo. These findings describe group patterns but research does not determine whether an individual will respond similarly.

Study Outcomes and Measurements Examined

The studies monitored outcomes related to systemic imbalance and focused on measurements related to blood pressure regulation. Research has primarily examined surrogate endpoints, which are measurements that can indicate changes in a condition but are not direct health outcomes like avoiding a stroke or a heart attack.

Specifically, the studies monitored the change in seated systolic (SBP) and diastolic (DBP) blood pressure from the starting point of the trial. These measurements reflect the endpoints chosen for the clinical evaluation of the combination. Furthermore, studies reported the proportion of participants whose blood pressure measurements reached certain pre-defined measurement goals. Some research also utilized 24-hour Ambulatory Blood Pressure Monitoring (ABPM), a tool that monitors blood pressure throughout the day and night, providing a wider set of data points about the measurements.

Long-Term Evidence and Durability of Follow-up

The majority of the pivotal clinical evaluation studies that provided initial data for this combination medicine were short-term, typically observing patients over periods ranging from eight to twelve weeks. These time frames were used to examine immediate patterns in blood pressure measurements.

Because initial RCTs involve short follow-up, evidence for long-term study is supplemented by intermediate to long-term observational studies and open-label extension phases. These studies examine how blood pressure measurements are maintained over longer intervals. However, data are still emerging, and long-term effects are not fully established. The research describes patterns of measurement changes observed within the defined study periods, but the evidence provides limited information regarding long-term outcomes related to cardiovascular morbidity and mortality (e.g., heart attack, stroke).

Evidence in Specific Patient Populations

Clinical research has included analyses to see how the findings relate to certain subgroups within the adult population.

Studies examined patterns in older adults (ge 65 years) who participated in the trials. Research also examined patients with co-occurring Type 2 Diabetes Mellitus, a group considered in the research as high-risk, to understand the patterns observed in these specific populations. The evidence contributes to understanding symptom patterns in these groups, but the results apply only to the populations studied, and subgroup findings are uncertain until confirmed by more extensive dedicated research.

Research Gaps and Unanswered Questions

Despite the existence of multiple short-term RCTs, certain aspects of the evidence base remain under-characterized.

  • Long-term clinical outcomes are not well established. As the primary studies monitored blood pressure (a surrogate outcome), there is limited long-term data specific to the fixed-dose combination regarding cardiovascular events such as heart attack or stroke.
  • The follow-up durations were limited in the pivotal efficacy trials, meaning that long-term patterns and sustained changes are less understood through high-certainty research.
  • Data for certain groups remain insufficient. The evidence is derived exclusively from adult populations, and data for the pediatric population (children under 18 years of age) remain insufficient. Furthermore, comparative evidence is lacking against all available alternative combination therapies.

Frequently Asked Questions (FAQ)

Common questions about Olmetec Plus (FAQ)


Q: Is Olmetec Plus the same drug as taking Olmesartan and Hydrochlorothiazide separately?

A: Olmetec Plus is officially designated as a fixed-dose combination (FDC) product. This means the two active ingredients, Olmesartan Medoxomil and Hydrochlorothiazide, are manufactured together in a single oral tablet.

While the components are chemically the same as if taken separately, the FDC formulation is intended for adults whose blood pressure is not adequately managed by a single ingredient alone.


Q: How long does it usually take for Olmetec Plus to start lowering blood pressure?

A: The full, maximum blood pressure lowering effect of the Olmesartan component may take approximately 8 weeks to achieve when used in monotherapy.

The fixed combination is often a therapeutic option when single-ingredient use has not provided adequate control. Dose changes are commonly evaluated by healthcare providers after two to four weeks of treatment at a specific strength.


Q: Can Olmetec Plus cause leg cramps or muscle aches?

A: Muscle pain or cramps are reported in official regulatory documents based on clinical experience with the medicine.

These effects, along with muscle fatigue, may be related to changes in the body's fluid and electrolyte balance, which is an expected consequence of the diuretic component.


Q: Is a persistent cough a known side effect of Olmetec Plus?

A: Clinical trial data has reported cough as a possible adverse reaction for Olmetec Plus.

Official information notes that the frequency and cause of cough associated with this medicine are considered distinct from the dry, persistent cough commonly linked to the related class of ACE inhibitor drugs.


Q: Are there specific food items or supplements that interact with Olmetec Plus?

A: The medicine can be taken with or without food. However, regulatory documents specifically identify potassium supplements and salt substitutes containing potassium as agents of concern, as the Olmesartan component can be a factor contributing to elevated potassium levels.

Additionally, the absorption of the diuretic component may be reduced by certain bile acid resins, such as cholestyramine.


Q: What does 'angioedema' mean, and is it a possible concern with Olmetec Plus?

A: The Olmesartan component belongs to the class of Angiotensin II Receptor Blockers (ARBs) and is associated with a risk of angioedema.

Angioedema is defined as a sudden, rapid swelling of the deep layers of the skin, such as in the face, lips, tongue, or throat. Regulatory warnings indicate that this reaction is potentially serious.


Q: Does the drug cause changes in weight, either gain or loss?

A: General weight change is not listed as a common side effect in the official safety profile.

However, substantial weight loss has been reported in very rare, post-marketing cases of a serious reaction called sprue-like enteropathy, which is marked by chronic, severe diarrhea.


Q: What is meant by a 'contraindication' for Olmetec Plus?

A: A contraindication describes a health condition or circumstance in which regulatory authorities state the medicine is officially not permitted for use.

Examples of contraindications for this medicine include the second and third trimesters of pregnancy, severe liver or kidney problems, or an inability to produce urine (anuria).


Q: What are the general expectations for blood pressure reduction after starting the medication?

A: Clinical studies have reported that treatment with the fixed-dose combination resulted in statistically significant reductions in both seated systolic (top number) and diastolic (bottom number) blood pressure when compared to a placebo.

These findings describe the general patterns of pressure reduction observed across groups of patients in the clinical trials.


Q: Does taking Olmetec Plus affect one's ability to drive or operate machinery?

A: The official product information notes that the medicine may cause side effects such as dizziness or fatigue.

These effects could potentially impair concentration and the ability to safely drive or operate complex machinery. The official product information recommends caution, especially during the initial phase of treatment or following a dose change.


Q: Can Olmetec Plus affect cholesterol or triglyceride levels?

A: The hydrochlorothiazide component is associated with potential changes in blood lipid levels.

Regulatory documents indicate that increases in cholesterol and triglycerides have been reported, effects that are generally considered reversible once the medicine is discontinued.


Q: What are the signs of a potential severe reaction that require immediate attention?

A: Signs of a potentially severe reaction include the rapid swelling of the face, lips, or throat (angioedema).

Another serious risk related to the diuretic component is the acute onset of decreased vision or eye pain, which may be a sign of secondary angle-closure glaucoma.


Q: Does the medication affect a man's sexual health?

A: Regulatory documents list impotence or erectile dysfunction as an adverse reaction associated with the hydrochlorothiazide component.

This side effect is reported in the safety profile, though it is typically classified as an uncommon or rare occurrence.


Q: Is it common to experience dry mouth while taking Olmetec Plus?

A: Dryness of the mouth is an officially listed adverse reaction for the medicine.

Because the product contains a diuretic, dry mouth is also noted as a potential indicator of a fluid or electrolyte imbalance.


Q: What are the recommendations for patients undergoing surgery while taking Olmetec Plus?

A: Official documentation specifies that caution should be exercised when the medication is used in patients undergoing surgery or general anesthesia.

This is due to the potential risk of severe hypotension (very low blood pressure) caused by the medicine's effect on the body's blood pressure regulation system during these procedures.


Q: Can Olmetec Plus lead to changes in mood or anxiety?

A: Officially listed adverse reactions include reports of depression and restlessness.

These effects may be related to mood or anxiety and can sometimes result from the electrolyte imbalances caused by the diuretic component of the medicine.

How should Olmetec Plus be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and disposing of Olmetec Plus (olmesartan medoxomil and hydrochlorothiazide) to maintain its quality and safety.

Storage Constraints

The tablets must be stored at a temperature below 25 C (77 F) and kept strictly out of the sight and reach of children. To ensure stability and protection from moisture, the medicine must remain in its original container or blister pack.

Disposal Instructions

Regulatory documents specify that any unused or expired medicinal product and associated waste material must be disposed of in accordance with local requirements. Medicines should not be disposed of via household rubbish or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olmetec Plus  found in:

A-Z Index: